grifols

Companies 17th February 2026

Moody’s raises Grifols’ corporate family rating from “B2” to “B1” and changes outlook from “positive” to “stable”

Link Securities | On Monday, credit rating agency Moody’s Ratings upgradedGrifols’ corporate family rating (CFR) from ‘B2’ to “B1”, reflecting the company’s continued operating performance and the ‘strength’ of its business fundamentals, Bolsamania.com reported yesterday. On the other hand, the agency has changed the outlook from ‘positive’ to ‘stable’. The rating agency explained that this change in rating reflects Grifols’ ‘solid operating performance, with strong revenue growth and profitability, which…

Companies 17th December 2025

EMA approves manufacture and distribution of plasma by Grifols Egypt

Link Securities | Spanish pharmaceutical company Grifols (GRF) reported on Tuesday that on 11 December 2025, the European Medicines Agency (EMA) had issued a Certificate of Compliance with EU legislation for plasma supplied by Grifols Egypt for Plasma Derivatives (GEPD), the joint venture established in 2020 between Grifols and Egypt’s National Service Projects Organisation. This certification was granted following a quality inspection of the plasma centres owned by GEPD and…

Companies 25th November 2025

Gotham City believes investigations into bearish attack on Grifols will not result in significant financial blow

Alphavalue/Divacons | Gotham City Research believes that the legal investigations stemming from its bearish attack on Grifols (GRF) in January 2024 will not result in a significant financial blow to the company, and has therefore ruled out making provisions for this possible contingency. This position is maintained despite the fact that the Spanish pharmaceutical company has initiated legal proceedings in the United States in which it is claiming millions in…

Companies 19th November 2025

FDA approves expansion of Grifols’ Thrombate III indication to include paediatric patients

Link Securities | Grifols (GRF) announced that the US Food and Drug Administration (FDA) has approved the expansion of the indication for Thrombate III, the company’s antithrombin III concentrate, to include paediatric patients diagnosed with hereditary antithrombin deficiency (HAD), according to Bolsamanía. With this expansion, Thrombate III becomes the first and only antithrombin concentrate approved for adults and paediatric patients with HAD, an often underdiagnosed blood clotting disorder that could…

Companies 29th September 2025

Neither Grifols, Rovi nor Almirall to be significantly affected by tariffs on pharmaceutical sector

Banc Sabadell | Trump said on social media that, starting on 1 October, all branded or patented pharmaceutical products will be subject to a 100% tariff, unless the company has begun to build a manufacturing facility in the United States. Assessment: Negative news due to the noise it may generate. However, details remain to be finalised, as we do not know whether companies that already had a presence in the…

Companies 16th September 2025

Grifols asks National Court to summon KPMG partners who signed 2021-2023 audits to testify in case

Alphavalue / Divacons | The Catalan company specialising in blood products is stepping up its legal offensive against Gotham City Research and has asked Court No. 4 of the National Court for the two KPMG partners who signed the 2021-2023 audits to testify in the case. The pharmaceutical company is seeking to strengthen its defence after the bearish attack that cost it around €9 million in January 2024. The Institute…

Companies, Relevant News Item 7th August 2025

CNMV imposes several fines on Grifols and directors for almost €1.4 million for deficiencies in financial reporting

Link Securities | The Spanish National Securities Market Commission (CNMV) has imposed several fines on Grifols (GRF) and its directors for a total of almost €1.4 million for deficiencies in its financial information and management reports, according to Expansión newspaper. The Official State Gazette (BOE) published on Wednesday a resolution dated 24 July by the CNMV announcing the penalties for very serious and serious infringements imposed on Grifols and several…

$Grifols to build new €160-million fractionation plant in Spain to double European production capacity$

Companies, Relevant News Item 18th July 2025

Grifols to build new €160-million fractionation plant in Spain to double European production capacity

Renta 4 | Grifols has resumed a project it has been working on since 2020 to build a new fractionation plant that will enable it to double its production capacity in Europe. The new factory will be located in Llica del Vall in the province of Barcelona, on land adjacent to its Parets del Valles complex, on an 80,000-square metre site that the company acquired for this purpose in 2018….

Relevant News Item 13th June 2025

Grifols’ takeover bid for Biotest, accepted by 2.11% of ordinary shares with voting rights (1.05% of capital)

Alphavalue/ Divacons | The Catalan plasma derivatives company announced yesterday that, once the period for acceptance of the delisting takeover bid for Biotest has ended, it will control 99.25% of the company. Biotest was delisted on 6 June, according to the information sent to the National Securities Market Commission (CNMV). The delisting offer was accepted by a total of 416,922 ordinary shares of Biotest and 3,002,804 non-voting preferred shares. In…

In the World 4th June 2025

US judge to investigate Gotham for defamation of Grifols in bearish report published in January 2024

Banco Sabadell: According to press reports, the U.S. District Court for the Southern District of New York has agreed to investigate Gotham City Research for defamation following the bearish report published on Grifols in January 2024. At the same time, it rejects four of the five charges brought by Grifols (illicit enrichment or interference with business relationships, among others). The court has also explicitly rejected the defendants’ attempt to invoke…

1 2 3 … 8 »